This Notice was RESCINDED on February 01, 2023, please see NOT-OD-23-067 that replaces it.

RESCINDED

RESCINDED - Clarification and Guidance for Applicants Preparing Applications for the FALL 2022 Due Dates During the COVID-19 Pandemic
Notice Number:
NOT-OD-23-008

Key Dates

Release Date:

October 25, 2022

Related Announcements

NOT-OD-22-112 - RESCINDED - Clarification and Guidance for Applicants Preparing Applications for the Summer 2022 Due Dates During the COVID-19 Pandemic

NOT-OD-22-046 - RESCINDED - Clarification and Guidance for Applicants Preparing Applications for the Spring 2022 Due Dates During the COVID-19 Pandemic

NOT-OD-21-180 - RESCINDED -Clarification and Guidance for Applicants Preparing Applications for the Fall 2021 Due Dates During the COVID-19 Pandemic

Issued by

NATIONAL INSTITUTES OF HEALTH (NIH)

Purpose

The NIH remains firmly committed to supporting the biomedical research enterprise as the nation implements the President's Guidelines for Re-Opening America Again. The purpose of this Notice is to extend the guidance provided earlier (NOT-OD-22-112) for applicants preparing applications for the May 2023 Council round, beginning with the September 25, 2022 due date.

Reviewers will continue to receive instructions to assume that constraints arising from the COVID-19 pandemic (e.g., lab occupancy restrictions, declines in patient accrual, etc.) will be resolved during the project period and thus should not affect their scores.

Therefore, NIH grant applications should NOT include contingency or recovery plans for problems resulting from the COVID-19 pandemic. However, applicants may address effects due to the pandemic on productivity or other scoreable issues in their Personal Statement in the NIH Biosketch. Reviewers will be instructed to take these pandemic-related circumstances into account when assessing applicants' productivity and other score-driving factors.

As with previous instructions, if needed, NIH staff will request and assess plans to resolve specific problems arising from the COVID-19 pandemic prior to funding.

Inquiries

Please direct all inquiries to:

NIH Review Policy Officer
Email: [email protected]